PHASE 2 EFFICACY AND SAFETY OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN COMBINATION WITH PEMBROLIZUMAB IN IMMUNE CHECKPOINT INHIBITOR-NAIVE PATIENTS WITH ADVANCED CANCERS

被引：20

作者：

O'Malley, David ^{[1
]}

Lee, Sylvia ^{[2
]}

Psyrri, Amanda ^{[3
]}

Sukari, Ammar ^{[4
]}

Thomas, Sajeve ^{[5
]}

Wenham, Robert ^{[6
]}

Gogas, Helen ^{[7
]}

Jazaeri, Amir ^{[8
]}

Monk, Bradley ^{[9
]}

Rose, Peter ^{[10
]}

Reuda, Antonio ^{[11
]}

Finckenstein, Friedrich Graf ^{[12
]}

Jagasia, Madan ^{[12
]}

Fiaz, Rana ^{[12
]}

Garelik, Brigid ^{[12
]}

Shi, Wen ^{[12
]}

Desai, Anjali ^{[12
]}

Sulur, Giri ^{[12
]}

Chen, Guang ^{[12
]}

Wu, Xiao ^{[12
]}

Jimeno, Antonio ^{[13
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Attikon Univ, Gen Hosp, Athens, Greece

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Orlando Hlth Canc Inst, Orlando, FL USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Natl & Kapodistrian Univ Athen, Athens, Greece

[8] MD Anderson Canc Ctr, Houston, TX USA

[9] US Oncol Network, Arizona Oncol, Phoenix, AZ USA

[10] Cleveland Clin, Columbud, OH USA

[11] Hosp Reg Univ Malag, Malaga, Spain

[12] Iovance Biotherapeut Inc, San Carlos, CA USA

[13] Univ Colorado, Sch Med, Aurora, CO USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.492

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

492

引用

页码：A523 / A524

页数：2

共 50 条

[1] Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naive patients with advanced melanoma.
Thomas, Sajeve Samuel
In, Gino Kim
Doger, Bernard
Haefliger, Simon
Martin-Liberal, Juan
Goldberg, Zelanna
Cacovean, Alex
Fiaz, Rana
Chen, Guang
Jagasia, Madan H.
Finckenstein, Friedrich Graf
Fardis, Maria
Jimeno, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
Thomas, Sajeve Samuel
Gogas, Helen
Hong, Young Ki
In, Gino Kim
Uribe, Bernard Doger de Speville
Furness, Andrew J. S.
Castano, Almudena Garcia
Haefliger, Simon
He, Kai
Medina, Theresa
Lawrence, Donald
Lee, Sylvia
Martin-Liberal, Juan
Finckenstein, Friedrich Graf
Gastman, Brian
Chou, Jeffrey
Fiaz, Rana
Catlett, Melissa
Chen, Guang
Terheyden, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma
Thomas, Sajeve S.
Chesney, Jason A.
Hamid, Omid
In, Gino K.
Shoushtari, Alexander N.
Samhouri, Yazan
Hari, Parameswaran
Ramsingh, Giridharan
Prabhakar, Prakash
Mclaughlin, Lauren
Warner, Allison Betof
CANCER RESEARCH, 2024, 84 (07)
[4] Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Larkin, J.
Dalle, S.
Sanmamed, M. F.
Wilson, M.
Hassel, J. C.
Kluger, H.
Orloff, M.
Weber, J. S.
Finckenstein, F. Graf
Hari, P.
Jagasia, M.
Yin, H.
Shi, W.
Sulur, G.
Wu, X.
Gontcharova, V.
Lewis, K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S935 - S936
[5] FIRST PHASE 2 RESULTS OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL; LN-145) MONOTHERAPY IN PATIENTS WITH ADVANCED, IMMUNE CHECKPOINT INHIBITOR-TREATED, NON-SMALL CELL LUNG CANCER (NSCLC)
Schoenfeld, Adam
Lee, Sylvia
Paz-Ares, Luis
Doger, Bernard
Gettinger, Scott
Haefliger, Simon
Orcurto, Angela
Sukari, Ammar
Papa, Sophie
Rodriguez Moreno, Juan Francisco
Finckenstein, Friedrich Graf
Jagasia, Madan
Fiaz, Rana
Sulur, Giri
Chen, Guang
Gontcharova, Viktoria
He, Kai
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A486 - A487
[6] TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
Thomas, Sajeve
Hong, Young Ki
Samhouri, Yazan
Larkin, James
Olson, David J.
In, Gino K.
Atkinson, Victoria
Lammers, Philip
Furness, Andrew J.
Martin-Liberal, Juan
Terheyden, Patrick
Poklepovic, Andrew S.
Nguyen, Ryan H.
Peretz, Idit
Butler, Marcus
Khattak, Adnan
Spain, Lavinia
Gaughan, E. M.
Wilson, Melissa
Dubay, John W.
Williams, Anja
Goff, Stephanie
Doolittle, Gary C.
Chesney, Jason
Finckenstein, Friedrich Graf
Chou, Jeffrey
Wu, Xiao
Sulur, Giri
Shi, Wen
Haanen, John
CANCER RESEARCH, 2024, 84 (07)
[7] A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma
Olson, Daniel
Hong, Young
Thomas, Sajeve Samuel
Martin-Liberal, Juan
Finckenstein, Friedrich Graf
Wu, Renee Xiao
Sulur, Giri
Shi, Wen
Larkin, James
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
Schoenfeld, Adam Jacob
Warner, Allison Betof
Chesney, Jason Alan
Thomas, Sajeve Samuel
Hamid, Omid
In, Gino Kim
Shoushtari, Alexander Noor
Samhouri, Yazan
Hari, Parameswaran N.
Ramsingh, Giridharan
Renard, Camille
Prabhakar, Prakash
Mclaughlin, Lauren
He, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Trial in Progress: A Phase 1/2 Study to Investigate the Safety and Efficacy of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients (Pts) with Advanced Solid Tumors
Schoenfeld, Adam J.
Warner, Allison Betof
Thomas, Sajeve S.
Hamid, Omid
In, Gino K.
Shoushtari, Alexander N.
Samhouri, Yazan
Hari, Parameswaran
Ramsingh, Giridharan
Prabhakar, Prakash
Mclaughlin, Lauren
Chesney, Jason A.
MOLECULAR THERAPY, 2024, 32 (04) : 881 - 881
[10] Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Chesney, Jason
Lewis, Karl D.
Kluger, Harriet
Hamid, Omid
Whitman, Eric
Thomas, Sajeve
Wermke, Martin
Cusnir, Mike
Domingo-Musibay, Evidio
Phan, Giao Q.
Kirkwood, John M.
Hassel, Jessica C.
Orloff, Marlana
Larkin, James
Weber, Jeffrey
Furness, Andrew J. S.
Khushalani, Nikhil, I
Medina, Theresa
Egger, Michael E.
Finckenstein, Friedrich Graf
Jagasia, Madan
Hari, Parameswaran
Sulur, Giri
Shi, Wen
Wu, Xiao
Sarnaik, Amod
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)

← 1 2 3 4 5 →